This benefit was observed in both the intent-to-treat population (6.2 vs. 4.9 months, hazard ratio [HR] 0.60) and in patients with PIK3CA/AKT/PTEN-altered tumors (9.0 vs. 4.9 months, HR 0.44), leading to the design of the ongoing randomized phase 3 trial exploring the combination in preselected triple-negative breast cancer with activation of the PI3K pathway (NCT03337724). The gene discussed is PIK3CA; the disease is triple-negative breast carcinoma.